Collaborative study for the establishment of the WHO 3(rd) International Standard for Endotoxin, the Ph. Eur. endotoxin biological reference preparation batch 5 and the USP Reference Standard for Endotoxin Lot H0K354.

An international collaborative study was organised jointly by the World Health Organization (WHO)/National Institute for Biological Standards and Control (NIBSC), the United States Pharmacopeia (USP) and the European Directorate for the Quality of Medicines & HealthCare (EDQM/Council of Europe) for the establishment of harmonised replacement endotoxin standards for these 3 organisations. Thirty-five laboratories worldwide, including Official Medicines Control Laboratories (OMCLs) and manufacturers enrolled in the study. Three candidate preparations (10/178, 10/190 and 10/196) were produced with the same material and same formulation as the current reference standards with the objective of generating a new (3(rd)) International Standard (IS) with the same potency (10 000 IU/vial) as the current (2(nd)) IS, as well as new European Pharmacopoeia (Ph. Eur.). and USP standards. The suitability of the candidate preparations to act as the reference standard in assays for endotoxin performed according to compendial methods was evaluated. Their potency was calibrated against the WHO 2(nd) IS for Endotoxin (94/580). Gelation and photometric methods produced similar results for each of the candidate preparations. The overall potency estimates for the 3 batches were comparable. Given the intrinsic assay precision, the observed differences between the batches may be considered unimportant for the intended use of these materials. Overall, these results were in line with those generated for the establishment of the current preparations of reference standards. Accelerated degradation testing of vials stored at elevated temperatures supported the long-term stability of the 3 candidate preparations. It was agreed between the 3 organisations that batch 10/178 be shared between WHO and EDQM and that batches 10/190 and 10/196 be allocated to USP, with a common assigned value of 10 000 IU/vial. This value maintains the continuity of the global harmonisation of reference materials and unitage for the testing of endotoxins in parenteral pharmaceutical products. Based on the results of the collaborative study, batch 10/178 was established by the European Pharmacopoeia Commission as the Ph. Eur. Endotoxin Biological Reference Preparation (BRP) batch 5. The same batch was also established by the Expert Committee on Biological Standardisation (ECBS) of WHO as the WHO 3(rd) IS for Endotoxin. Batch 10/190 was adopted as the USP Endotoxin Reference Standard, lot H0K354 and vials from this same batch (10/190) will serve as the United States Food and Drug Administration (USFDA) Endotoxin Standard, EC-7.

Standardization of water purification in the central dialysis fluid delivery system: validation and parametric method.

The central dialysis fluid delivery system (CDDS) has been mainly used for hemodialysis therapy in Japan. Validation and a parametric method are necessary for the quality control of dialysis fluid in CDDS. Validation is a concept for the assurance of system compatibility and product quality, and is defined as follows: the manufacturing and quality control methods including the system design and equipment of the manufacturing facility, manufacturing procedure and processes. Confirmed results must be kept within acceptable limits and they must be documented in a record. Important parameters for validating CDDS include: (1) setting the sterilized area; (2) decision of sterilization level; (3) confirmation of the maximum bio-burden; (4) performance of endotoxin retentive filter and reverse osmosis (RO) module, and (5) checkpoints of purity of dialysis water in the system. Taking the concept of validation and a parametric method in the management of CDDS into consideration enables the supply the purified dialysis fluid or the online prepared substitution fluid that meet the 2008 standards of the Japanese Society for Dialysis Therapy.

Endotoxin limits in formulations for preclinical research.

This brief commentary discusses a review of the current status on endotoxin limits, a critical parameter, for formulations to be administered to animals. The endotoxin units set by United States Pharmacopoeia (USP), and the techniques specified by USP for endotoxin testing are described. Endotoxin limits for preclinical research animal models were derived based on the threshold pyrogenic human dose of 5 E.U. per kg. The limits calculated would act as a guideline for endotoxin limits in preclinical species. A quick reference chart for endotoxin limits is included to provide a guideline for endotoxin limits for animal models used in preclinical research. Derivation of endotoxin limits from K/M for doses and animal models not included in the chart could be calculated as described.

beta-Glucans in standardized allergen extracts.

BACKGROUND: Allergen extracts contain variable quantities of bacterial endotoxin. Recent studies have suggested that (1-->3)-beta-D-glucans (beta-glucans), also microbial cell wall components, may have adjuvant properties that could affect allergen immunotherapy. OBJECTIVE: To determine the quantities of beta-glucans in standardized allergen extracts. MATERIALS AND METHODS: Ninety-four lots of 13 standardized allergen extracts were tested for beta-glucan content by Glucatell assay, and for endotoxin content by a specific, chromogenic formulation of the Limulus amebocyte lysate test. RESULTS: Standardized allergen extracts contain variable quantities of endotoxins and beta-glucans. As in our previous work, endotoxin activity was greatest in cat pelt and Dermatophagoides farinae, and least in the pollens. There was no correlation between endotoxin and beta-glucan levels (r = 0.1887; P = 0.07). beta-Glucan content was highest for grass pollen (median content, 10.6 ng/ml; range, 0.4-41.8 ng/ml), ragweed pollen (32.9 ng/ml; range, 6.5-41.2 ng/ml), and cat pelt (25.5 ng/ml; range, 16.7-41.1 ng/ml), and lowest for cat hair (4.9 ng/ml; range, 1.2-10.3 ng/ml), D. farinae (1.2 ng/ml; range, 0.4-5.2 ng/ml) and Dermatophagoides pteronyssinus (1.8 ng/ml; range, 0.4-6.7 ng/ml). CONCLUSIONS: beta-Glucans are present in standardized allergen extracts. The effects of these quantities of beta-glucans on allergen immunotherapy and allergen skin testing require further study.

Indoor and outdoor air quality assessment of four wastewater treatment plants.

The study assessed the air quality of four wastewater treatment plants (WWTPs) by monitoring levels of hydrogen sulfide (H2S) and endotoxin. Samples were taken over a 1-year period (2001-2002). The unit operations at each WWTP were categorized as: (a) grit removal, (b) primary clarification, (c) biological treatment, (d) secondary clarification, (e) sludge dewatering, and (f) digestion. Temperature and humidity were monitored simultaneously, whereas airborne H2S and endotoxin were monitored at each of the six unit operations in each plant. Carbonaceous biochemical oxygen demand (CBOD) and total incoming flow of the day of visit were also recorded. The geometric means of H2S concentration were less than 1 ppm and endotoxin ranged from 6-1247 EU/m3. A mixed model analysis of covariance (ANCOVA) was used for the statistical analysis. While temperature was not associated with the levels of both contaminants, humidity was influential on the level of H2S (p < 0.01) but not of endotoxin. CBOD did not affect the levels of either contaminant; however, incoming flows showed an association with the levels of H2S (p < 0.05). The concentrations of H2S in the six unit operations were statistically different, whereas endotoxin did not show any differences in concentrations between units. Individual comparisons proved that concentrations of H2S in the grit removal and sludge dewatering unit operations were statistically higher than the other operations. Overall, the concentrations of H2S varied depending on total incoming flow, humidity, and different unit operations. This trend was not observed for endotoxin. The results showed that the factors analyzed affected concentrations of H2S and endotoxin differently. Therefore, different control methods for endotoxin and H2S need to be considered to effectively reduce their concentrations at WWTPs.

Exposure to bioaerosols and noise at a Finnish dry waste treatment plant.

Repeated measurements were carried out during two different campaigns between 1998 and 2001 to assess the occupational hygiene at a Finnish dry waste treatment plant. The analytical determinations were done in four different places within the processing hall of the plant: near a conveyor belt, near a jigger screen, near an after-crusher and near a bailer. Measurements were also carried out in a coffee room for employees. Concentrations of bacteria, fungi and actinomycetes were determined by two methods (six-stage impactor and Camnea method) and levels of endotoxins, dust and noise were also investigated. High concentrations of microbes and endotoxins and the noise level were found to be a real problem in the waste processing hall. Microbe concentrations were highest during management of the dry waste fraction. Endotoxin concentrations all exceeded the threshold value of 200 EU m(-3) irrespective of the measurement place, with the only exception near the after-crusher where the average concentration was always as low as 60 EU m(-3). The noise level exceeded the Finnish threshold value of 85 dBA. Problems were not easily solved through technical modifications and more radical improvements are needed. Improvements in reliability are also required in the measuring methods before their application in waste treatment plants. In particular, a new method of dust collection is recommended.

A review of drinking-water-associated endotoxin, including potential routes of human exposure.

In the past decade efforts have been made to reduce the formation of harmful disinfection byproducts during the treatment and distribution of drinking water. This has been accomplished in part by the introduction of processes that involve the deliberate encouragement of indigenous biofilm growth in filters. In a controlled environment, such as a filter, these biofilms remove compounds that would otherwise be available as disinfection byproduct precursors or support uncontrolled biological activity in distribution systems. In the absence of exposure to chlorinated water, most biofilm bacteria are gram negative and have an outer layer that contains endotoxin. To date, outbreaks of waterborne endotoxin-related illness attributable to contamination of water used in hemodialysis procedures have been only infrequently documented, and occurrences linked to ingestion or through dermal abrasions could not be located. However, a less obvious conduit, that of inhalation, has been described in association with aerosolized water droplets. This review summarizes documented drinking-water-associated incidents of endotoxin exposure attributable to hemodialysis and inhalation. Typical endotoxin levels in water and conditions under which substantial quantities can enter drinking water distribution systems are identified. It would appear that endotoxin originating in tap water can be inhaled but at present there is insufficient information available to quantify potential health risks.

[The Endotoxin 10000 Reference Standard of the National Institute of Health Sciences (the Japanese Pharmacopoeia Endotoxin 10000 Reference Standard) (Control 0211)].

To establish the fifth lot (Control 0211) of the Endotoxin 10000 Reference Standard of the National Institute of Health Sciences (the Japanese Pharmacopoeia Endotoxin 10000 Reference Standard), a candidate standard (CS) was prepared and then evaluated. The potency of the CS was assayed against USP Endotoxin Reference Standard (Lot G-1) and defined a s containing approximately 16,000 endotoxin units (EU) per vial by a collaborative study in which 5 laboratories participated. Based on the results, the CS was authorized to be the fifth lot of the Endotoxin 10000 Reference Standard containing 16,000 EU per vial.

[The Endotoxin 100 Reference Standard of the National Institute of Health Sciences (the Japanese Pharmacopoeia Endotoxin 100 Reference Standard) (Control 0201)].

To establish the third lot (Control 0201) of the Endotoxin 100 Reference Standard of the National Institute of Health Sciences (the Japanese Pharmacopoeia Endotoxin 100 Reference Standard), a candidate standard (CS) was prepared and then evaluated. The potency of the CS was assayed against USP Endotoxin Reference Standard (Lot G-1) and defined as containing approximately 130 endotoxin units (EU) per vial by a collaborative study in which 5 laboratories participated. Based on the results, the CS was authorized to be the third lot of the Endotoxin 100 Reference Standard containing 130 EU of endotoxin per vial.

Disposable TSM-biosensor based on viscosity changes of the contacting medium.

The thickness shear mode (TSM)-sensor responds to changes of mechanical properties of the material contacting the surface of the sensor. One of the material properties is the viscosity of a liquid. Abiosensor based on the TSM-resonator for the detection of endotoxin has been developed. It exploits the viscosity-density change during the reaction of endotoxin with limulus amebocyte lysate (LAL). The effect of surface properties of the sensor has been investigated to achieve better output signals. It is shown that the sensor requires a hydrophilic surface to get a better coupling between the sensor and the LAL-endotoxin solution. The TSM biosensor is able to detect an endotoxin concentration as low as 100 fg/ml by using only 50-microl standard LAL solution. The disadvantages of reusable sensors, such as the contamination from previous measurement of endotoxin and the cost of the regeneration or reclining processes of the sensor, have been eliminated by using a cost effective disposable TSM-sensor.

Determination of Cry9C protein in corn-based foods by enzyme-linked immunosorbent assay: interlaboratory study.

The performance of a commercially available enzyme-linked immunosorbent assay kit (Enviro-Logix) was assessed for the determination of Cry9C protein, which is produced by the genetically modified corn StarLink, in 8 types of corn-based foods (starch, refined oil, soft tortillas, tortilla chips, corn flakes, corn puffs, corn muffins, and corn bread) in an interlaboratory study involving 7 laboratories in the United States. The assay kit is a double antibody sandwich and is based on the specific interaction between antibody and antigen. The Cry9C protein analyte is sandwiched between 2 antibodies, one to capture the analyte and the other is conjugated to the enzyme, horseradish peroxidase. The enzyme uses tetramethylbenzidine/peroxide for color development. A strong acid stopping reagent is then used to change the color from blue to a stable yellow. The intensity of the color is proportional to the concentration of the Cry9C protein. In this study blind duplicates of control samples (blank material prepared from non- StarLink corn), spiked samples (blank material with the addition of Cry9C protein), and samples containing incurred analyte (products prepared with StarLink corn) were analyzed. Cry9C protein from 2 different sources was used to spike the food products. Cry9C protein produced and purified from a bacterial host was used to prepare spiked test samples at 2.72 and 6.8 ng/g. Cry9C protein from StarLink corn flour was used to prepare spiked samples at 1.97 ng/g. Average recoveries for samples spiked with corn flour Cry9C protein at 1.97 ng/g ranged from 73 to 122%, within-laboratory relative standard deviations (RSDr) ranged from 6 to 22%, and between-laboratories relative standard deviations (RSDR) ranged from 16 to 56%. Average recoveries for samples spiked with bacterial Cry9C protein at 2.72 and 6.8 ng/g ranged from 27 to 96% and from 32 to 113%, respectively; RSDr values ranged from 10 to 35% and from 7 to 38%, respectively; and the RSDR ranged from 28 to 84% and 15 to 75%, respectively. The incurred test samples were found to contain Cry9C protein at levels ranging from 0.8 to 3187 ng/g depending on the product, RSDr values ranged from 5 to 16% and RSDR values ranged from 11 to 71%. Results of the statistical analysis indicate that this method is applicable to the determination of Cry9C protein in the 8 types of collaboratively studied corn-based products containing Cry9C protein (from StarLink) at levels of > or =2 ng/g.

[The Endotoxin 100 Reference Standard of the National Institute of Health Sciences (the Japanese Pharmacopoeia Endotoxin 100 Reference Standard) (Control 0101)].

To establish the second lot (Control 0101) of the Endotoxin 100 Reference Standard of the National Institute of Health Sciences (the Japanese Pharmacopoeia Endotoxin 100 Reference Standard), a candidate standard (CS) was prepared and then evaluated. The potency of the CS was assayed against USP Endotoxin Reference Standard (Lot G-1) and defined as containing approximately 100 endotoxin units (EU) per vial by a collaborative study in which 5 laboratories participated. Based on the results, the CS was authorized to be the second lot of the Endotoxin 100 Reference Standard containing 100 EU of endotoxin per vial.

[The Endotoxin 10,000 Reference Standard of the National Institute of Health Sciences (the Japanese Pharmacopoeia Endotoxin 10,000 Reference Standard) (Control 0001)].

To establish the fourth lot (Control 0001) of the Endotoxin 10,000 Reference Standard of the National Institute of Health Sciences (the Japanese Pharmacopoeia Endotoxin 10,000 Reference Standard), a candidate standard (CS) was prepared and then evaluated. The potency of the CS was assayed against USP Endotoxin Reference Standard (Lot G-1) and defined as containing approximately 20,000 endotoxin units (EU) per vial by a collaborative study in which 5 laboratories participated. Based on the results, the CS was authorized to be the fourth lot of the Endotoxin 10,000 Reference Standard containing 20,000 EU per vial.

[The Endotoxin Reference Standard of the National Institute of Health Sciences (the Japanese Pharmacopoeia Endotoxin Reference Standard) (Control 971)].

The third lot (Control 971) of the Endotoxin Reference Standard of the National Institute of Health Sciences (the Japanese Pharmacopoeia Endotoxin Reference Standard) was prepared. The potency of the new lot was assayed against USP Endotoxin Reference Standard (EC-6) and defined as containing 13,000 endotoxin units (EU) per vial by a collaborative study of 7 laboratories.

The views and policy of the Japanese control authorities on the three Rs.

NIH Japan has tested and regulated the three Rs of animal experiments in the development and control of biological products in a stepwise manner. (1) The number of monkeys was reduced from 108 to 72 for the neurovirulence test of OPV in each type, since paralysed monkeys inoculated intraspinally revealed a linear relationship between average scores of the lumbar lesion and cumulated paralysis occurrence ratio (%). (2) Rabbits for the pyrogen test were replaced by the endotoxin test for PPF, albumin and interferon products. The endotoxin is measured by the parallel line assay method using both turbidimetric kinetic and colorimetric methods. (3) Histopathological examination was introduced to the abnormal toxicity test as a refinement. Mean body weight loss of two guinea pigs inoculated with five ml. of an albumin product in each was far below the mean weight of pooled guinea pigs used (P < or = 0.01) and appeared repeatedly. The histopathological examination showed focal necrosis in the liver. This finding was suggestive of the presence of endotoxin in the product. The product contained 0.1 EU/ml of endotoxin. The same amount of the reference endotoxin produced a similar change in guinea pigs. The mechanism of the liver cell damage by endotoxin has been investigated by an in vitro method.

Sensitive quantitation of endotoxin by enzyme-linked immunosorbent assay with monoclonal antibody against Limulus peptide C.

Limulus peptide C, a 28-amino-acid fragment of coagulogen formed by the reaction of endotoxin with Limulus amebocyte lysate, was synthesized, and a monoclonal antibody against it was raised. A new microassay for endotoxin was developed, using this antibody in an enzyme-linked immunosorbent assay for generated peptide C-like immunoreactivity. A linear relationship between absorbance and endotoxin concentration was obtained. Control standard endotoxin in water could be detected to a level of 0.001 endotoxin unit per ml. The endotoxin levels in plasma samples from normal humans, rabbit, mice, and guinea pigs were generally found to be below the detection limit of 0.01 endotoxin unit per ml of plasma. The color and turbidity of specimens did not interfere with the assay. The consumption of Limulus amebocyte lysate in the assay was less than 5% of that in the gel-clot and chromogenic assays. With raw lysate, which was much more stable in solution than chloroform-treated lysate, the assay was still highly sensitive to endotoxin but was totally unresponsive to natural glucans. The monoclonal antibody cross-reacted with peptide C-like immunoreactivity generated in Tachypleus amebocyte lysate, which gave equal sensitivity in the endotoxin assay.

A new sensitive microplate assay of plasma endotoxin.

We have developed a microplate method for determining endotoxin in platelet-rich plasma-using Endospecy, an endotoxin-specific chromogenic Limulus test reagent. Nonspecific activators and inhibitors of the test were eliminated by exposing samples (5 microliters) to the alkali reagent consisting of KOH, CaCl2, Triton X-100, ethyleniminepolymer and N,N-bis(2-hydroxyethyl)glycine. The recoveries of various endotoxins were almost complete and not enhanced by dilution. The dose-response curve was linear over endotoxin concentrations of 2-400 pg/ml with good precision (C.V. less than 5.0%). Normal human plasmas (n = 30) contained less than 5.0 pg/ml of endotoxin in reference to that of Escherichia coli 0111: B4. All plasma samples with high concentration of endotoxin by a conventional method showed high values by the microplate assay as well. Since it does not require centrifugation, the new treatment allows the whole reactions to proceed on the same microplate. This permits us to apply the Limulus test to an automated assay system, making plasma endotoxin determination simpler and more rapid than a conventional test tube method.

Specific assay for endotoxin using immobilized histidine and Limulus amebocyte lysate.

The LAL test is inhibited or enhanced by many substances. To overcome these problems, we have developed a specific endotoxin assay method using an ultrafiltration unit, a fluorometric LAL reagent, and immobilized histidine (which is a specific adsorbent for endotoxins). This method is composed of two steps. The first step is the adsorption of endotoxins. Using immobilized histidine, endotoxins are quantitatively adsorbed on the adsorbent, and the adsorbed endotoxins are separated from LAL-inhibiting or -enhancing substances by the ultrafiltration unit. The second step is the reaction of adsorbed endotoxins with the LAL reagent. The endotoxins adsorbed on immobilized histidine are directly reacted with the LAL reagent in a filter cup and show enough activity for assay. The reproducibility and the accuracy of this method are high, and the recovery of endotoxins from a sample solution is more than 95%. The new endotoxin assay method using immobilized histidine can be utilized for the determination of endotoxins in a solution containing LAL-inhibiting or -enhancing substances such as amino acids and antibiotics instead of requiring employment of the more common gel-clot technique.

Testing medical disposables using the Limulus Amoebocyte Lysate (LAL) test.

Plastic, single-use devices intended for the administration of drugs or for the removal or transfer of body fluids must be free of pyrogenic contaminants. Unfortunately, very little information is available regarding tests to detect such contaminants. For this reason, many manufacturers of medical disposables must rely on their own discretion when they devise methods for extracting these substances from their products. This article discusses the use and value of the Limulus Amoebocyte Lysate (LAL) test for estimating the concentration and extraction of bacterial endotoxins in disposable medical devices. When bioburden-control procedures are applied to products manufactured to GMP requirements, batch testing of products for pyrogenicity may not be essential.

[National Institute of Hygienic Sciences Standard (the Japanese Pharmacopoeia Standard) "Endotoxin Reference Standard" (Control 891)].

The second "Endotoxin Reference Standard" (Control 891) of the National Hygienic Sciences (Japanese Pharmacopoeia Standard) was prepared. As a result of the test of its potency against the preceding lot of the Reference Standard (Control 881), the second "Endotoxin Reference Standard" (Control 891) containing 16000 endotoxin units per vial was authorized.